Send the following on WhatsApp
Continue to Chat天演藥業在SITC 2022上公布抗CTLA-4新表位抗體ADG116臨床數據,針對經多線治療的難治性腫瘤患者展示出高度差異化的安全性與抗腫瘤活性 https://geneonline.news/%e5%a4%a9%e6%bc%94%e8%97%a5%e6%a5%ad%e5%9c%a8sitc-2022%e4%b8%8a%e5%85%ac%e5%b8%83%e6%8a%97ctla-4%e6%96%b0%e8%a1%a8%e4%bd%8d%e6%8a%97%e9%ab%94adg116%e8%87%a8%e5%ba%8a%e6%95%b8%e6%93%9a%ef%bc%8c/